MindWalk (NASDAQ:HYFT) Coverage Initiated by Analysts at JonesTrading

JonesTrading started coverage on shares of MindWalk (NASDAQ:HYFT) in a research report sent to investors on Thursday,Benzinga reports. The brokerage issued a buy rating and a $5.00 price objective on the stock.

A number of other analysts also recently issued reports on the stock. HC Wainwright reissued a “buy” rating on shares of MindWalk in a report on Friday, March 13th. Weiss Ratings began coverage on shares of MindWalk in a report on Wednesday, January 14th. They issued a “sell (d-)” rating for the company. UBS Group reissued a “buy” rating on shares of MindWalk in a report on Friday, March 13th. Finally, Zacks Research raised shares of MindWalk from a “strong sell” rating to a “hold” rating in a report on Monday, February 16th. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $5.00.

MindWalk Stock Up 3.1%

NASDAQ HYFT opened at $1.32 on Thursday. The company has a quick ratio of 3.64, a current ratio of 3.74 and a debt-to-equity ratio of 0.21. The company has a market cap of $60.93 million, a P/E ratio of -6.60 and a beta of 0.63. MindWalk has a 12-month low of $0.40 and a 12-month high of $3.25. The firm has a 50-day simple moving average of $1.23.

MindWalk (NASDAQ:HYFT) last posted its quarterly earnings data on Thursday, March 12th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.02). The business had revenue of $3.00 million during the quarter, compared to the consensus estimate of $3.50 million. MindWalk had a negative net margin of 66.79% and a negative return on equity of 69.37%.

Institutional Trading of MindWalk

Institutional investors and hedge funds have recently made changes to their positions in the company. Virtu Financial LLC bought a new stake in shares of MindWalk during the 4th quarter worth approximately $51,000. Bridgeway Capital Management LLC bought a new stake in shares of MindWalk during the 4th quarter worth approximately $91,000. Bank of Montreal Can lifted its holdings in shares of MindWalk by 81.0% during the 4th quarter. Bank of Montreal Can now owns 54,750 shares of the company’s stock worth $100,000 after acquiring an additional 24,500 shares during the period. XTX Topco Ltd lifted its holdings in shares of MindWalk by 118.6% during the 4th quarter. XTX Topco Ltd now owns 81,721 shares of the company’s stock worth $149,000 after acquiring an additional 44,331 shares during the period. Finally, Jane Street Group LLC lifted its holdings in shares of MindWalk by 147.3% during the 4th quarter. Jane Street Group LLC now owns 161,202 shares of the company’s stock worth $293,000 after acquiring an additional 96,018 shares during the period. Institutional investors own 6.70% of the company’s stock.

About MindWalk

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation.